LCC & EUROFINS DISCOVERY STRATEGIC ALLIANCE

LCC and Eurofins Discovery have merged their novel compound libraries and screening capabilities, to support:

  • FBLD (Fragment Based Lead Discovery)
  • VLS (Virtual Library Screening)
  • Hetero Bifunctional Molecular Development (eg. PROTACs, Molecular glues, ADC's)

Eurofins


eurofins.com

Eurofins is the world leader in food, environment, pharmaceutical and cosmetic products testing, and in agroscience CRO services. It is also one of the global independent market leaders in testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences, and for supporting clinical studies. With access to over 200,000 analytical techniques, Eurofins aims to provide their customers with high-quality services, accurate results on time and expert advice from their highly skilled workforce.

Discovery Services & Specialties

Eurofins Discovery has supported Drug Discovery research for over 40 years. Eurofins is recognized as the industry leader for providing drug discovery researchers the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling.

The Eurofins Discovery capabilities, expertise, knowledge and skill sets enable the company to provide clients the benefit of being able to work with a single outsourcing provider (CRO) for all their drug discovery programs.
  • 1,800 products
  • 3,500 drug discovery services including: ADME toxicology, safety pharmacology and efficacy, In vitro and cell-based phenotypic assays, custom proteins and assay development capabilities
  • Experts in product and clinical discoveries, from lead qualification to product launch
  • Support for a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins & enzymes

Our Alliance

Eurofins Discovery and LCC will combine their proprietary linker sets, fragment libraries and virtual compound collections utilizing Eurofins Discovery's innovative drug discovery solutions to provide a high-quality screening platform for hit identification and lead optimization.

Biotech and pharma companies worldwide will significantly benefit from this strategic alliance through access to enhanced libraries, which will increase the likelihood of identifying tractable starting points, with the potential for rapid optimization in a fully integrated setting.

White Paper

Exploring New Fragment Chemical Space: A Comparative Study of LCC’s Fragment Library with Established Libraries and Published Hits

Fragment based drug design (FBDD) is an approach used in drug discovery to develop biologically potent …

DOWNLOAD PDF

Eurofins Logo